Inspire Medical Systems has seen its share price move sharply over several timeframes, which naturally puts the focus on whether the current valuation is supported by the cash it can generate. With the stock price at US$74.32 at the last close, the key issue now is how that market tag lines up with the business's future cash flows.
-
Over the past 5 years, Inspire Medical Systems shares have fallen 70.2%, which puts a lot of weight on whether the underlying cash flow story still backs the remaining equity value.
-
The company's model, which depends on converting medical device demand into durable cash generation, can significantly influence how much of today's price reflects long term cash flows versus nearer term expectations.
-
Prefer to judge Inspire Medical Systems on earnings? See what Inspire Medical Systems's 15.9x P/E says about the price .
The stock's next move may depend on whether Inspire Medical Systems' current share price can be explained by the cash flows implied by a Discounted Cash Flow (DCF) intrinsic value estimate.
If you want a wider set of ideas alongside Inspire Medical Systems while still focusing on valuation and quality, a targeted stock screen such as 35 high quality undervalued stocks can be a useful second starting point for research.
Is Inspire Medical Systems Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Inspire Medical Systems can return to shareholders over time, adjusted back to today's dollars. Latest twelve month free cash flow is about $116.4 million, and analysts feeding into this framework expect future cash generation to stay in a similar range rather than rely on very aggressive expansion assumptions.
Projected free cash flows in the model trend around the low to mid $100 million level over the next decade. This paints a picture of a business expected to sustain meaningful cash generation rather than swing sharply higher or lower. On that set of inputs, the DCF estimate comes out modestly above the current share price of US$74.32, so the model suggests some upside based purely on the cash flows it assumes. Find out what Inspire Medical Systems could be worth using our Discounted Cash Flow (DCF) estimate .
The Inspire Medical Systems Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Inspire Medical Systems pick up where the DCF puzzle leaves off and spell out what kind of future for growth, margins and earnings would need to play out for the shares to look meaningfully higher or lower than today's price, all housed on the Community page. Rather than relying on a single multiple or output, each Narrative lays out the key moving parts behind its fair value view so you can later compare those assumptions with the actual numbers the company reports.
Community views on Inspire Medical Systems pull in opposite directions, with one group seeing scope for upside and another flagging meaningful downside risk.
Bull case: 9% undervalued
"The integration of SleepSync cloud-based patient management and ongoing R&D enhancements will markedly improve patient outcomes and therapy personalization, boosting long-term physician loyalty and system retention..."
Discover why this Narrative puts Inspire Medical Systems at 9% undervalued .
Bear case: 23% overvalued
"Changes in reimbursement dynamics, especially regarding Medicare and shifting CPT codes, have created temporary barriers but also hint at a long-term risk, payer and regulatory pressure could limit coverage..."
Explore why this Narrative puts Inspire Medical Systems at 23% overvalued .
The Inspire Medical Systems story is not complete if you ignore potential red flags
Price and cash flow only tell part of the story for Inspire Medical Systems, since our broader checks have surfaced specific risk alerts that deserve your attention before you lean too hard on valuation alone. Take a closer look at 1 major warning sign before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include INSP .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
